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a  b  s  t  r  a  c  t
INTRODUCTION:  Mixed  large  cell  neuroendocrine  neoplasms  of the  rectum  are rare  and  aggressive  neo-
plasms.  Survival  is poor due to  the  high  rate  of  lymph  node  metastases  and  distant  metastases  at  the  time
of  diagnosis.
PRESENTATION  OF  CASE:  We  report  a  case  of  a 50-year-old  male  patient  with  a mixed  large  cell  neu-
roendocrine  carcinoma  with  squamous  cell  carcinoma  of the  rectum  located  8 cm  from  the anal  verge,
treated  with  low  anterior  resection  and  total  mesorectal  excision  with  free  surgical  margins.  There
were  lymph  nodes  metastases  but  no  distant  metastases  at the  time of  diagnosis.  The  patient  refused
to  receive  adjuvant  chemotherapy  and died  6 months  later  due  to  liver  failure  as  a result  of  multiple
hepatic  metastases.
DISCUSSION:  There  are  not  known  predisposing  factors  for  the  development  of neuroendocrine  rectal
carcinoma.  A  neuroendocrine  carcinoma  of the rectum  is  a rare  tumor  with  an incidence  of less than
0.1%  of  all  colorectal  malignancies.  The  median  survival  ranges  from  5 to  10.4  months  in  several  studies
and  there  are  not  sufﬁcient  data  in  bibliography  about  ideal adjuvant  therapy  after  resection  of mixed
squamous  large  cell  neuroendocrine  carcinoma  of the  rectum.
CONCLUSION: Low  anterior  resection  and total  mesorectal  excision  with  free  surgical  margins  in  the  pres-
ence  of  lymph  nodes  metastasis  is not  a sufﬁcient  treatment  for rectal  neuroendocrine  carcinoma.  More
studies  should  be done  in order  to determine  the  ideal  adjuvant  treatment  of these  rare  and  aggressive
tumors.
© 2013 The Authors. Published by Elsevier Ltd on behalf of Surgical Associates Ltd. 
 . Introduction
Neuroendocrine carcinoma (NEC) is a poor differentiated, high
rade malignant neoplasm composed of tumor cells that express
ndocrine markers (synaptophysin, chromogranin A) and show
arked cellurar atypia, frequent necrosis and high proliferative
ctivity.1 We  can recognize small cell NEC, large cell NEC and mixed
EC. Mixed adenoendocrine tumors are rare and generalizations
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ttp://dx.doi.org/10.1016/j.ijscr.2013.08.021about their behavior cannot be made.2 Moreover, squamous differ-
entiation has not been observed in large cell NECs until now, while
the coexistence of small cell carcinomas with an associated small
cell carcinoma component has been described.3 We report the ﬁrst
case in bibliography of a mixed large cell NEC with squamous cell
carcinoma of the rectum, a highly aggressive and rare tumor.
2.  Presentation of case
A  50-year-old male patient was  admitted to our hospital with
the major complaint of mild rectal bleeding for the last 5 days.
He described changes in bowel habits during the last month, but
no weight loss. He had free past surgical history and had never
undertaken a colonoscopy examination. Basic laboratory tests of
Open access under CC BY-NC-SA license.peripheral blood on admission were normal (hematocrit 43%).
The serum levels of Cancer Antigen (CA) 19-9, Carcinoembrionic
Antigen (CEA) and a-fetoprotein (AFP) were within normal range.
Digital examination was negative.
Ltd . Open access under CC BY-NC-SA license. 
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ﬁFig. 1. Picture from colonoscopy showing the ulcerative tumor.
Colonoscopy was performed, which revealed an ulcerative mass
f 6 cm in length (Fig. 1), with its lower margin located 8 cm
rom the anal verge. Microscopic analysis of biopsy specimens
howed morphological and immunohistochemical characteristics
f poorly differentiated neuroendocrine carcinoma (chromogranin
+, Synaptophysin A+). The proliferation marker Ki-67 was  dif-
usely stained and was approximately 80%. Cytokeratines C5/6
ere negatives. Computed tomography (CT) scan of the abdomen
evealed pathological enlarged mesorectal lymph nodes (Fig. 2)
ithout obvious liver metastases, while chest CT scan was normal.
A low anterior resection with total mesorectal excision and
ymph nodes dissection was performed, with free macroscopic
urgical margins. The specimen included an ulcerative tumor
 cm × 4 cm,  with its lower edge located 2 cm from the distal sur-
ical margin. The tumor had elastic consistency, compact form,
rayish and partially brownish color, and inﬁltrated the entire mus-
ular wall. There was extension of the tumor to pericolic fat in many
ites. Four of 24 resected lymph nodes were positive for metastatic
umor. There were, also, neoplastic emboli in lymphatics and ves-
els.
ig. 2. Computed tomography (CT) scan of the abdomen showing enlarged mesorec-
al lymph nodes (red arrow). (For interpretation of the references to color in this
gure legend, the reader is referred to the web version of the article.)Fig. 3. The large cell neuroendocrine carcinoma on the left and the squamous cell
carcinoma on the right (H&E ×200).
After microscopic examination and immunohistochemical
study, the diagnosis of poorly differentiated large cell neuroen-
docrine carcinoma was  established. It was composed of isolated
large cells with scart eosinophil cytoplasm and nucleus with large
prominent nucleolus, while there were areas of organoid, nes-
ting and trabecular pattern. Surprisingly, squamous cell carcinoma
coexisted, representing 5–10% of tumor population (Fig. 3). The
mitotic rate was  >20 per high power ﬁelds and Ki-67 was  80%. It
was classiﬁed as G3 neuroendocrine carcinoma according to WHO
classiﬁcation 2010 of tumors of the digestive system, and pT3N1M0
according to the AJCC/2010 staging system. The immunophenotype
of neuroendocrine carcinoma was: Synaptophysin (+), Chromo-
grnin A (+), CD56 (+), CK5/6 (−), CD.X-2 (+) in few cells, CK20 (+)
in a small percentage of cells. The immunophenotype of squamous
cell carcinoma component was: Synaptophysin (−), Chromogranin
A (−), CD56 (−), CK5/6 (+), CDX2 (+), p63 (−), CK20 (−).
The patient had an uneventful recovery and was  discharged
on the 10th postoperative day. He refused to receive adjuvant
chemotherapy despite oncologist recommendations, and died 6
months later due to liver failure as a result of multiple hepatic
metastases.
3. Discussion
Neuroendocrine rectal tumors (NRTs) constitute 7.2–27% of all
neuroendocrine tumors. Incidence in general population ranges
from 0.24 to 1.65 per 100.000 persons.4 According to the WHO
classiﬁcation 2010 neoplasms of the digestive system with neu-
roendocrine differentiation are subdivided into neuroendocrine
tumors (NETs), neuroendocrine carcinomas (NECs) and mixed neu-
roendocrine carcinomas (MANECs).2 The term NETs includes well
differentiated tumors (carcinoids), and their grade is either G1
(Grade 1) or G2 (Grade 2). The term NECs includes poorly differen-
tiated, high grade, small and large cell neuroendocrine carcinomas,
and their grade is always G3 (Grade 3). We  can use the term MANEC
only when there are both neuroendocrine and non-neuroendocrine
epithelial malignant components and each component exceeds
30%. In our case, we had a G3 large cell NEC. The diagnosis of MANEC
could not be established, because the squamous cell carcinoma
represented the 5–10% of tumors cells.
A NEC of the rectum is a rare tumor with an incidence of less than
0.1% of all colorectal malignancies.5 We  have found less than 100
cases in bibliography. According to Bernick, only 22 cases (0.03%
of total colorectal cancers) of small cell neuroendocrine carcinoma
and 16 cases (0.02%) of large cell neuroendocrine carcinoma were
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dentiﬁed from their database of colorectal cancers that included
pproximately 6500 patients, in a period of 23 years. Only 14 cases
ere located in the rectum.5 In a recent review of 10 years manage-
ent of neuroendocrine rectal tumors, only 2/37 patients (5.4%) of
he total NRTs had tumors that were classiﬁed as neuroendocrine
arcinoma.6
Li et al. analyzed the pathologic characteristics of mixed colo-
ectal glandular-neuroendocrine tumors. A total of 87 cases were
ncluded in their study, after search strategy. None of these tumors
as found in the rectum, with the majority of them located in the
ight colon (56%) and the left colon (41%). In addition to this, only
% had an ulcerating lesion, as in our case. Squamous cell carci-
oma was mixed with glandular epithelial component in 12% of
otal cases.7 Mixed G3 large cell NEC with squamous carcinoma of
he rectum is extremely rare. We  have not noticed any other case
n bibliography.
There are no known predisposing risk factors associated to the
evelopment of neuroendocrine tumors. Genetic factors may  play
he major role in susceptibility to NET formation. Women  with
iabetes and positive family history for cancer have an increased
ncidence of gastric NETs. This is attributed to the increased genetic
usceptibility for NETs development in women as compared to
en.8 Our patient had a free family history for cancer and no
iabetes. Especially for MANEC, there is the theory of a stem cell
recursor. This is based on the presence of transitional tumor cells
hat revealed common immunoreactivity for CA 19-9, keratin 19,
luster of differentiation protein 117 and epithelial cell adhesion
olecule.9
Neuroendocrine tumors may  be found incidentally at
olonoscopy (40%), or patients may  present with rectal bleed-
ng, changes in bowel habits, tenesmus, discomfort and weight
oss. Features of carcinoid syndrome are very rare for rectal
umors. Lesions <2 cm with a low grade and intact muscularis
ropria can mostly be removed by local resection. Rectal tumors
2 cm,  T3 or T4 stage, G3 or rectal tumors with locoregional
ymph node involvement should be treated similarly to adeno-
arcinoma. For rectal NETs >2 cm,  anterior resection with total
esorectal excision or abdominoperineal exstirpation should be
erformed.1
Neuroendocrine carcinomas of the colon and rectum are
xtremely aggressive neoplasms.5,11,12 The median survival ranges
rom 5 to 10.4 months in several studies.5,10 The longest 6-
onth survival is 58%11 and the longest 1-year survival is
6% in the Bernick’s study.5 This is due to the high rate of
ymph node metastases, that exceeds 60% in all studies, and
he high rate of distant metastases at diagnosis that exceeds
9%11 and reaches 73% in the Gaffey’s study.12 In our case, the
atient had lymph nodes metastases without distant metastases
t the time of diagnosis. Nevertheless, the carcinoma showed
 highly aggressive behavior and the patient died 6 months
ater.
We have to underline that the NEC in our case had Ki-67 label
ndex 80%, thus explaining its aggressive behavior and that the
atient had a large sized NEC mixed with a squamous carcinoma
omponent. Furthermore, the patient did not receive any adju-
ant therapy. There are not sufﬁcient data in bibliography about
urvival and ideal adjuvant therapy after resection of mixed squa-
ous large cell NEC of the rectum. It seems that these neoplasms
ehave as other NECs.13 According to the NANETS consensus guide-
ines, the combination of etoposide and cisplatin is the ﬁrst line
herapy for extrapulmonary NECs, without speciﬁc reference in
ixed squamous NECs.14 Various other chemotherapeutic regi-
ens have been used in a small number of patients with NECs
ith good results. A case of effective use of chemoradiother-
py for the treatment of large cell NEC of the rectum has been
ublished.15
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4. Conclusion
Low anterior resection and total mesorectal excision with free
surgical margins in the presence of lymph nodes metastasis is not
a sufﬁcient treatment for rectal neuroendocrine carcinoma. More
studies with larger number of patients with mixed rectal NECs
should be done in order to determine the ideal treatment of these
rare and aggressive tumors.
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